* Mylan files notice for generic version of Lidoderm
* Endo says reviewing details of notice
Jan 31 (Reuters) - Endo Pharmaceuticals Holdings Inc (ENDP.O) said it intends to defend its medicine patch Lidoderm’s intellectual property rights after Mylan Technologies Inc (MYL.O) applied to produce a generic version of the patch.
Endo said its partners Teikoku Seiyaku Co and Teikoku Pharma USA Inc received a Paragraph IV certification notice from Mylan Inc’s (MYL.O) unit, advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of Lidoderm.
The company said it is reviewing details of the notice and intends to “vigorously” defend Lidoderm’s intellectual property rights.
Paragraph IV certification notice refers to U.S. Patent Nos. 5,741,510 and 5,827,529, which cover the formulation of Lidoderm, a topical patch to relieve the pain of postherpetic neuralgia launched in 1999.
The patents, registered with the U.S. Food and Drugs Administration (FDA), is set to expire in March 2014 and October 2015, respectively. (Reporting by Fareha Khan; Editing by Erica Billingham)